SCHEMBL1132332

SCHEMBL1132332

CN[C@@H](CO)CN(C)C(C)(C)c1ccccc1OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.36
AGTR1 P30556 1/20 0.36
CYP1A2 P05177 1/20 0.36
GAA P10253 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
ATM Q13315 1/20 0.33
CASR P41180 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA4 P22748 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12566084 0.88 ALDH1A1 (0.37) ALDH1A1LMNAAGTR1CYP1A2GAA
SCHEMBL12608597 0.87 ALDH1A1 (0.36) ALDH1A1LMNAAGTR1CYP1A2GAA
SCHEMBL1133034 0.86 LMNA (0.34) ALDH1A1LMNAAGTR1CYP1A2GAA
SCHEMBL1133037 0.86 LMNA (0.34) ALDH1A1LMNAAGTR1CYP1A2GAA
SCHEMBL1132936 0.82 ALDH1A1 (0.37) ALDH1A1GAAMEN1KMT2ASLC6A2
SCHEMBL1132966 0.81 AGTR1 (0.38) ALDH1A1LMNAAGTR1CYP1A2GAA
SCHEMBL1132372 0.80 AGTR1 (0.37) ALDH1A1LMNAAGTR1CYP1A2GAA
SCHEMBL1132369 0.80 AGTR1 (0.37) ALDH1A1LMNAAGTR1CYP1A2GAA
SCHEMBL12609236 0.78 LMNA (0.36) ALDH1A1LMNAAGTR1CYP1A2GAA
SCHEMBL12565862 0.78 AGTR1 (0.36) ALDH1A1LMNAAGTR1CYP1A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299035-B2 10a-azalide compound having 4-membered ring structure TAISHO PHARMACEUTUCAL CO., LTD. (JP) 2012-10-30 US disclosed
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-06-23 US disclosed
EP-2287173-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE Taisho Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152239-A1 10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE ELOVL3, ELOVL5, SCD5 ALDH1A1 3050/4885LMNA 1555/4885AGTR1 4520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.